Molecular dynamics studies of the protein-protein interactions in inhibitor of κb kinase-β

Journal of Chemical Information and Modeling

Volumn 54, Issue 2, 2014, Pages 562-572

  Jones, Michael R ^a   Liu, Cong ^a   Wilson, Angela K ^a  

^a UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL ACTIVATION; CONFORMATIONS; DIMERIZATION; DIMERS; ENZYME ACTIVITY;

ATOMISTIC MOLECULAR DYNAMICS SIMULATIONS; COARSE-GRAINED; CONFORMATIONAL CHANGE; GLOBAL STABILITY; IMMUNE RESPONSE; INTERMOLECULAR INTERACTIONS; PROTEIN-PROTEIN INTERACTIONS; STRUCTURE ACTIVITY RELATIONSHIPS;

MOLECULAR DYNAMICS;

ADENOSINE TRIPHOSPHATE; I KAPPA B KINASE;

ARTICLE; CHEMISTRY; ENZYME STABILITY; HYDROGEN BOND; METABOLISM; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; THERMODYNAMICS;

ADENOSINE TRIPHOSPHATE; ENZYME STABILITY; HYDROGEN BONDING; I-KAPPA B KINASE; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; THERMODYNAMICS;

EID: 84894684740     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci400720n     Document Type: Article

References (89)

1. Baldwin, A. S., Jr. Series introduction: The transcription factor NF-κB and human disease J. Clin. Invest 2001, 107, 3-6
2. de Martin, R.; Schmid, J. A.; Hofer-Warbinek, R. The NF-kappaB/Rel family of transcription factors in oncogenic transformation and apoptosis Mutat. Res. 1999, 437, 231-243
3. Ghosh, S.; May, M. J.; Kopp, E. B. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses Annu. Rev. Immunol. 1998, 16, 225-260
4. Sullivan, J. C.; Kalaitzidis, D.; Gilmore, T. D.; Finnerty, J. R. Rel homology domain-containing transcription factors in the cnidarian Nematostella vectensis Dev. Genes Evol. 2007, 217, 63-72
5. Baldwin, A. S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB J. Clin. Invest. 2001, 107, 241-246
6. Ghosh, S.; Karin, M. Missing pieces in the NF-kappaB puzzle Cell 2002, 109 Suppl, S81-96
7. Gilmore, T. D.; Garbati, M. R. Inhibition of NF-kappaB signaling as a strategy in disease therapy Curr. Top. Microbiol. Immunol. 2011, 349, 245-263
8. Gilmore, T. D.; Wolenski, F. S. NF-kappaB: where did it come from and why? Immunol. Rev. 2012, 246, 14-35
9. Rayet, B.; Gelinas, C. Aberrant Rel/NFkb genes and activity in human cancer Oncogene 1999, 18, 6938-6947
10. Gilmore, T. D. Introduction to NF-kappaB: Players, pathways, perspectives Oncogene 2006, 25, 6680-6684
11. Perkins, N. D.; Gilmore, T. D. Good cop, bad cop: The different faces of NF-kappaB Cell Death Differ. 2006, 13, 759-772
12. Gilmore, T. D.; Gerondakis, S. The c-Rel transcription factor in development and disease Genes Cancer 2011, 2, 695-711
13. Gilmore, T. D.; Kalaitzidis, D.; Liang, M. C.; Starczynowski, D. T. The c-Rel transcription factor and B-cell proliferation: A deal with the devil Oncogene 2004, 23, 2275-2286
14. Gilmore, T. D. Introduction: The Rel/NF-kappaB signal transduction pathway Semin. Cancer Biol. 1997, 8, 61-62
15. Gilmore, T. D.; Koedood, M.; Piffat, K. A.; White, D. W. Rel/NF-kappaB/IkappaB proteins and cancer Oncogene 1996, 13, 1367-1378
16. Gilmore, T. D. NF-kappa B, KBF1, dorsal, and related matters Cell 1990, 62, 841-843
17. Sun, S. C. Non-canonical NF-kappaB signaling pathway Cell Res. 2011, 21, 71-85
18. Beg, A. A.; Ruben, S. M.; Scheinman, R. I.; Haskill, S.; Rosen, C. A.; Baldwin, A. S., Jr. I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: A mechanism for cytoplasmic retention Genes Dev. 1992, 6, 1899-1913
19. Beg, A. A.; Baldwin, A. S., Jr. The I kappa B proteins: Multifunctional regulators of Rel/NF-kappa B transcription factors Genes Dev. 1993, 7, 2064-2070
20. Zabel, U.; Henkel, T.; Silva, M. S.; Baeuerle, P. A. Nuclear uptake control of NF-kappa B by MAD-3, an I kappa B protein present in the nucleus EMBO J. 1993, 12, 201-211
21. Huguet, C.; Crepieux, P.; Laudet, V. Rel/NF-kappa B transcription factors and I kappa B inhibitors: Evolution from a unique common ancestor Oncogene 1997, 15, 2965-2974
22. Baeuerle, P. A.; Henkel, T. Function and activation of NF-kappa B in the immune system Annu. Rev. Immunol. 1994, 12, 141-179
23. Siebenlist, U.; Franzoso, G.; Brown, K. Structure, regulation and function of NF-kappa B Annu. Rev. Cell Biol. 1994, 10, 405-455
24. Karin, M. How NF-kappaB is activated: The role of the IkappaB kinase (IKK) complex Oncogene 1999, 18, 6867-6874
25. Israel, A. The IKK complex, a central regulator of NF-κB activation Cold Spring Harbor Perspect. Biol. 2010, 2, a000158-1-a000158-14
26. Nishikori, M. Classical and alternative NF-kB activation pathways and their roles in lymphoid malignancies J. Clin. Exp. Hematol. 2005, 45, 15-24
27. Gamble, C.; McIntosh, K.; Scott, R.; Ho, K. H.; Plevin, R.; Paul, A. Inhibitory kappa B Kinases as targets for pharmacological regulation Br. J. Pharmacol. 2012, 165, 802-819
28. Karin, M.; Delhase, M. The I kappa B kinase (IKK) and NF-kappa B: Key elements of proinflammatory signalling Semin. Immunol. 2000, 12, 85-98
29. May, M. J.; Ghosh, S. Rel/NF-kB and IkB proteins: An overview Semin. Cancer Biol. 1997, 8, 63-73
30. Zandi, E.; Rothwarf, D. M.; Delhase, M.; Hayakawa, M.; Karin, M. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation Cell 1997, 91, 243-252
31. Hacker, H.; Karin, M. Regulation and function of IKK and IKK-related kinases Sci. Signaling 2006, re13
32. Mercurio, F.; Zhu, H.; Murray, B. W.; Shevchenko, A.; Bennett, B. L.; Li, J.; Young, D. B.; Barbosa, M.; Mann, M.; Manning, A.; Rao, A. IKK-1 and IKK-2: Cytokine-activated IkappaB kinases essential for NF-kappaB activation Science 1997, 278, 860-866
33. Hayden, M. S.; Ghosh, S. Signaling to NF-kappaB Genes Dev. 2004, 18, 2195-2224
34. Zandi, E.; Chen, Y.; Karin, M. Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: Discrimination between free and NF-kappaB-bound substrate Science 1998, 281, 1360-1363
35. Delhase, M.; Karin, M. The I kappa B kinase: a master regulator of NF-kappa B, innate immunity, and epidermal differentiation Cold Spring Harbor Symp. Quant. Biol. 1999, 64, 491-503
36. Johnson, L. N.; Noble, M. E.; Owen, D. J. Active and inactive protein kinases: Structural basis for regulation Cell 1996, 85, 149-158
37. Pandey, M. K.; Sung, B.; Kunnumakkara, A. B.; Sethi, G.; Chaturvedi, M. M.; Aggarwal, B. B. Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis Cancer Res. 2008, 68, 5370-5379
38. Gupta, S. C.; Prasad, S.; Reuter, S.; Kannappan, R.; Yadav, V. R.; Ravindran, J.; Hema, P. S.; Chaturvedi, M. M.; Nair, M.; Aggarwal, B. B. Modification of cysteine 179 of IkappaBalpha kinase by nimbolide leads to down-regulation of NF-kappaB-regulated cell survival and proliferative proteins and sensitization of tumor cells to chemotherapeutic agents J. Biol. Chem. 2010, 285, 35406-35417
39. Byun, M. S.; Choi, J.; Jue, D. M. Cysteine-179 of IkappaB kinase beta plays a critical role in enzyme activation by promoting phosphorylation of activation loop serines Exp. Mol. Med. 2006, 38, 546-552
40. Harikumar, K. B.; Kunnumakkara, A. B.; Ahn, K. S.; Anand, P.; Krishnan, S.; Guha, S.; Aggarwal, B. B. Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells Blood 2009, 113, 2003-2013
41. Xu, G.; Lo, Y. C.; Li, Q.; Napolitano, G.; Wu, X.; Jiang, X.; Dreano, M.; Karin, M.; Wu, H. Crystal structure of inhibitor of kappaB kinase beta Nature 2011, 472, 325-330
42. Nolen, B.; Taylor, S.; Ghosh, G. Regulation of protein kinases; controlling activity through activation segment conformation Mol. Cell 2004, 15, 661-675
43. Boutros, T.; Chevet, E.; Metrakos, P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: Roles in cell growth, death, and cancer Pharmacol. Rev. 2008, 60, 261-310
44. Pearson, G.; Robinson, F.; Beers Gibson, T.; Xu, B. E.; Karandikar, M.; Berman, K.; Cobb, M. H. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions Endocr. Rev. 2001, 22, 153-183
45. Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W. MAP kinase signalling pathways in cancer Oncogene 2007, 26, 3279-3290
46. Ferrell, J. E., Jr.; Bhatt, R. R. Mechanistic studies of the dual phosphorylation of mitogen-activated protein kinase J. Biol. Chem. 1997, 272, 19008-19016
47. Kalia, M.; Kukol, A. Structure and dynamics of the kinase IKK-beta-A key regulator of the NF-kappa B transcription factor J. Struct. Biol. 2011, 176, 133-142
48. Kornev, A. P.; Taylor, S. S.; Ten Eyck, L. F. A helix scaffold for the assembly of active protein kinases Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 14377-14382
49. Steichen, J. M.; Iyer, G. H.; Li, S.; Saldanha, S. A.; Deal, M. S.; Woods, V. L., Jr.; Taylor, S. S. Global consequences of activation loop phosphorylation on protein kinase A J. Biol. Chem. 2010, 285, 3825-3832
50. Scheeff, E. D.; Bourne, P. E. Structural evolution of the protein kinase-like superfamily PLoS Comput. Biol. 2005, 1, e49-1-e49-23
51. Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the "gatekeeper door": Exploiting the active kinase conformation J. Med. Chem. 2010, 53, 2681-2694
52. Palermo, N. Y.; Natarajan, A. Beyond the frog: The evolution of homology models of human IKKbeta Bioorg. Med. Chem. Lett. 2011, 21, 6081-6084
53. Berman, H. M. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-242
54. Molecular Operating Environment (MOE), 2011.10; Chemical Computing Group Inc.: Montreal, Quebec, Canada, 2011.
55. Wang, J.; Cieplak, P.; Kollman, P. A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J. Comput. Chem. 2000, 21, 1049-1074
56. Ponder, J. W.; Case, D. A. Force fields for protein simulations Adv. Protein Chem. 2003, 66, 27-85
57. Salomon-Ferrer, R.; Case, D. A.; Walker, R. C. An overview of the Amber biomolecular simulation package Wiley Interdiscip. Rev.: Comput. Mol. Sci. 2013, 3, 198-210
58. Case, D. A.; Cheatham, T. E.; Darden, T.; Gohlke, H.; Luo, R.; Merz, K. M.; Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R. J. The Amber biomolecular simulation programs J. Comput. Chem. 2005, 26, 1668-1688
59. Soga, S.; Shirai, H.; Kobori, M.; Hirayama, N. Use of amino acid composition to predict ligand-binding sites J. Chem. Inf. Model. 2007, 47, 400-406
60. Durand, E.; Derrez, E.; Audoly, G.; Spinelli, S.; Ortiz-Lombardia, M.; Raoult, D.; Cascales, E.; Cambillau, C. Crystal structure of the VgrG1 actin cross-linking domain of the Vibrio cholerae type VI secretion system J. Biol. Chem. 2012, 287, 38190-38199
61. Meagher, K. L.; Redman, L. T.; Carlson, H. A. Development of polyphosphate parameters for use with the AMBER force field J. Comput. Chem. 2003, 24, 1016-1025
62. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field J. Comput. Chem. 2004, 25, 1157-1174
63. Homeyer, N.; Horn, A. H.; Lanig, H.; Sticht, H. AMBER force-field parameters for phosphorylated amino acids in different protonation states: Phosphoserine, phosphothreonine, phosphotyrosine, and phosphohistidine J. Mol. Model. 2006, 12, 281-289
64. Kenzaki, H.; Koga, N.; Hori, N.; Kanada, R.; Li, W.; Okazaki, K.; Yao, X.; Takada, S. CafeMol: A coarse-grained biomolecular simulator for simulating proteins at work J. Chem. Theory Comput. 2011, 7, 1979-1989
65. Joung, I. S.; Cheatham, T. E. Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations J. Phys. Chem. B 2008, 112, 9020-9041
66. Berendsen, H. J. C.; Grigera, J. R.; Straatsma, T. P. The missing term in effective pair potentials J. Phys. Chem. 1987, 91, 6269-6271
67. Hornak, V.; Abel, R.; Okur, A.; Strockbine, B.; Roitberg, A.; Simmerling, C. Comparison of multiple Amber force fields and development of improved protein backbone parameters Proteins 2006, 65, 712-725
68. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera-a visualization system for exploratory research and analysis J. Comput. Chem. 2004, 25, 1605-1612
69. Prall, M. VMD: A graphical tool for the modern chemists J. Comput. Chem. 2001, 22, 132-134
70. Miller, B. R.; McGee, T. D.; Swails, J. M.; Homeyer, N.; Gohlke, H.; Roitberg, A. E. MMPBSA.py: An efficient program for end-state free energy calculations J. Chem. Theory Comput. 2012, 8, 3314-3321
71. Hawkins, G. D.; Cramer, C. J.; Truhlar, D. G. Pairwise solute descreening of solute charges from a dielectric medium Chem. Phys. Lett. 1995, 246, 122-129
72. Hawkins, G. D.; Cramer, C. J.; Truhlar, D. G. Parametrized models of aqueous free energies of solvation based on pairwise descreening of solute atomic charges from a dielectric medium J. Phys. Chem. 1996, 100, 19824-19839
73. Tsui, V.; Case, D. A. Theory and applications of the generalized born solvation model in macromolecular simulations Biopolymers 2000, 56, 275-291
74. Onufriev, A.; Bashford, D.; Case, D. A. Exploring protein native states and large-scale conformational changes with a modified Generalized Born model Proteins: Struct., Funct., Bioinf. 2004, 55, 383-394
75. Massova, I.; Kollman, P. A. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding Perspect. Drug Discovery Des. 2000, 18, 113-135
76. Krissinel, E.; Henrick, K. Inference of macromolecular assemblies from crystalline state J. Mol. Biol. 2007, 372, 774-797
77. Krissinel, E. Crystal contacts as nature's docking solutions J. Comput. Chem. 2010, 31, 133-143
78. Mandal, S.; Moudgil, M.; Mandal, S. K. Rational drug design Eur. J. Pharmacol. 2009, 625, 90-100
79. Durrant, J. D.; McCammon, J. A. Molecular dynamics simulations and drug discovery BMC Biol. 2011, 9, 71-1-71-9
80. Borhani, D. W.; Shaw, D. E. The future of molecular dynamics simulations in drug discovery J. Comput.-Aided Mol. Des. 2012, 26, 15-26
81. Hao, G. F.; Yang, G. F.; Zhan, C. G. Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem Drug Discovery Today 2012, 17, 1121-1126
82. Chodera, J. D.; Mobley, D. L.; Shirts, M. R.; Dixon, R. W.; Branson, K.; Pande, V. S. Alchemical free energy methods for drug discovery: progress and challenges Curr. Opin. Struct. Biol. 2011, 21, 150-160
83. Mobley, D. L.; Chodera, J. D.; Dill, K. A. The confine-and-release method: Obtaining correct binding free energies in the presence of protein conformational change J. Chem. Theory Comput. 2007, 3, 1231-1235
84. Tozzini, V. Minimalist models for proteins: A comparative analysis Q. Rev. Biophys. 2010, 43, 333-371
85. Kamerlin, S. C. L.; Vicatos, S.; Dryga, A.; Warshel, A. Coarse-Grained (multiscale) simulations in studies of biophysical and chemical systems Annu. Rev. Phys. Chem. 2011, 62, 41-64
86. Li, F.; Gangal, M.; Juliano, C.; Gorfain, E.; Taylor, S. S.; Johnson, D. A. Evidence for an internal entropy contribution to phosphoryl transfer: a study of domain closure, backbone flexibility, and the catalytic cycle of cAMP-dependent protein kinase J. Mol. Biol. 2002, 315, 459-469
87. Li, F.; Gangal, M.; Jones, J. M.; Deich, J.; Lovett, K. E.; Taylor, S. S.; Johnson, D. A. Consequences of cAMP and catalytic-subunit binding on the flexibility of the A-kinase regulatory subunit Biochemistry 2000, 39, 15626-15632
88. Polley, S.; Huang, D.; Hauenstein, A. V.; Fusco, A. J.; Zhong, X.; Vu, D.; Schroefelbauer, B.; Kim, Y.; Hoffmann, A.; Verma, I. M.; Ghosh, G.; Huxford, T. A structural basis for IkB kinase 2 activation via oligomerization dependent trans auto-phosphorylation PLoS Biol. 2013, 11, e1001581-1-e1001581-13
89. Liu, S.; Misquitta, Y. R.; Olland, A.; Johnson, M. A.; Kelleher, K. S.; Kriz, R.; Lin, L. L.; Stahl, M.; Mosyak, L. Crystal structure of a human IkappaB kinase beta asymmetric dimer J. Biol. Chem. 2013, 288, 22758-22767